In glioblastoma diagnostics, genomics is already used to verify whether the tumor is IDH‐ and H3‐wildtype or exhibits other genetic features such as TERT promoter mutation, EGFR gene amplification, or +7/−10 chromosome copy‐number changes [2]. This evidence concerns the gene EGFR and glioblastoma.